Working ability and educational level among long-term survivors of testicular cancer (TCSS) compared to a general population (GenPop) This is an ASCO Meeting Abstract from the 2004 ASCO Annual Meeting ...
image: Octapharma USA presented research at the American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting evaluating the efficacy and safety of cutaquig® (Immune Globulin Subcutaneous ...
To determine the dose-limiting toxicity (DLT), maximum tolerated dose, recommended dose (RD) and preliminary evidence of activity of escalating doses of irinotecan (CPT-11) fixed-dose-rate infusional ...
Fabrazyme (agalsidase beta) is a brand-name drug prescribed for Fabry disease in adults and some children. Fabrazyme comes as an IV infusion that’s given by a healthcare professional. The dosage ...
Intravenous infusion systems are a cornerstone of modern clinical care, ensuring that fluids and medications are administered at precise rates to meet patient needs. These systems are integral to a ...
A team of scientists from the Pennsylvania State University, USA, recently analyzed the pharmacodynamics and pharmacokinetics of antiviral drug remdesivir using computational models. Based on the ...
After being found effective over longer durations with smaller doses, this study found that nipocalimab infusions resulted in a tolerable safety profile and remained effective even in shorter ...
Phase I/II study is tracking to meet primary endpoints RECCE ® 327 at 3,000mg over 15 minutes marks the fastest infusion rate of a high concentration Cohort fully recruited with remaining subjects to ...
Leqembi (lecanemab-irmb) is a prescription drug that’s used to treat Alzheimer’s disease. The drug comes as a liquid that’s given as an infusion into a vein. It’s usually given once every 2 weeks.
Truxima (rituximab-abbs) is prescribed to treat certain cancers and immune system conditions. The drug is a liquid that a healthcare professional injects into a vein. Doctors determine the dosing ...
The Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for Gazyva (obinutuzumab) to include a new dosing regimen for patients with follicular ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback